{"drugs":["Saizen","Serostim","Somatropin, Mammalian Derived","Zorbtive"],"mono":{"0":{"id":"925054-s-0","title":"Generic Names","mono":"Somatropin, Mammalian Derived"},"1":{"id":"925054-s-1","title":"Dosing and Indications","sub":[{"id":"925054-s-1-4","title":"Adult Dosing","mono":"<ul><li>safety or efficacy data in patients treated with Serostim(R) continuously for more than 48 weeks, or treated intermittently have not been established<\/li><li><b>Cachexia associated with AIDS:<\/b> Serostim(R), dosed once daily, or every other day (fewer side effects): body weight less than 35 kg, 0.1 mg\/kg SUBQ at bedtime; 35 to 45 kg, 4 mg SUBQ at bedtime; 45 to 55 kg, 5 mg SUBQ at bedtime; over 55 kg, 6 mg SUBQ at bedtime<\/li><li><b>Growth hormone deficiency:<\/b> Saizen(R): initial, not more than 0.005 mg\/kg\/day SUBQ or IM; after 4 weeks, may increase up to a MAX dose of 0.01 mg\/kg\/day SUB or IM as tolerated<\/li><li><b>Growth hormone deficiency:<\/b> guideline (The Endocrine Society): individualize dose, start low and titrate according to clinical response, side effects and insulin-like growth factor-I (IGF-I) levels<\/li><li><b>Growth hormone deficiency:<\/b> guideline (AACE): younger than 30 years, 0.4 to 0.5 mg\/day SUBQ; 30 to 60 years of age, 0.2 to 0.3 mg\/day SUBQ; older than 60 years of age, 0.1 to 0.2 mg\/day SUBQ; patients with diabetes or who are susceptible to glucose intolerance, start with 0.1 to 0.2 mg\/day<\/li><li><b>Growth hormone deficiency:<\/b> guideline (AACE): increase dose in increments of 0.1 to 0.2 mg\/day at 1 to 2 month intervals based on clinical response, serum insulin-like growth factor levels, side effects, and individual considerations such as glucose intolerance<\/li><li><b>Short bowel syndrome:<\/b> Zorbtive(TM): approximately 0.1 mg\/kg SUBQ daily for 4 weeks; MAX daily dose 8 mg<\/li><\/ul>"},{"id":"925054-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>safety and effectiveness in pediatric patients with short bowel syndrome have not been established<\/li><li>safety or efficacy data in patients treated with Serostim(R) continuously for more than 48 weeks, or treated intermittently have not been established<\/li><li><b>Cachexia associated with AIDS:<\/b> Serostim(R), dosed once daily, or every other day (fewer side effects): body weight less than 35 kg, 0.1 mg\/kg SUBQ at bedtime; 35 to 45 kg, 4 mg SUBQ at bedtime; 45 to 55 kg, 5 mg SUBQ at bedtime; over 55 kg, 6 mg SUBQ at bedtime<\/li><li><b>Growth hormone deficiency:<\/b> Saizen(R): 0.06 mg\/kg SUBQ or IM 3 times\/wk<\/li><\/ul>"},{"id":"925054-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>geriatric:<\/b> dose selection should be cautious, usually starting at the low end of the dosing range; may require longer time intervals and smaller dose increments<\/li><li><b>estrogen status:<\/b> women, especially those receiving concomitant oral estrogen therapy, may require higher doses<\/li><li><b>(Serostim(R)) adverse effects:<\/b> reduce the total daily dose or the number of doses per week<\/li><li><b>(Zorbtive(TM)) short bowel syndrome with moderate fluid retention:<\/b> reduce dose by 50%<\/li><li><b>(Zorbtive(TM)) short bowel syndrome with severe toxicities:<\/b> discontinue for up to 5 days; upon resolution of symptoms, resume at 50% of original dose; permanently discontinue if severe toxicity recurs or does not disappear within 5 days<\/li><\/ul>"},{"id":"925054-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Cachexia associated with AIDS<\/li><li>Growth hormone deficiency<\/li><li>Short bowel syndrome<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><br\/>Fat maldistribution - HIV infection<br\/>"}]},"3":{"id":"925054-s-3","title":"Contraindications\/Warnings","sub":[{"id":"925054-s-3-9","title":"Contraindications","mono":"<ul><li>acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma; increased mortality has been reported<\/li><li>acute respiratory failure; increased mortality has been reported<\/li><li>Prader-Willi syndrome, in patients who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment; sudden death has been reported<\/li><li>active malignancy<\/li><li>active proliferative or severe non-proliferative diabetic retinopathy<\/li><li>closed epiphyses in pediatric patients<\/li><li>hypersensitivity to mammalian-derived somatropin or any excipients<\/li><li>hypersensitivity to benzyl alcohol-containing diluent<\/li><\/ul>"},{"id":"925054-s-3-10","title":"Precautions","mono":"<ul><li>Cardiovascular:<\/li><li>-- fluid retention may occur<\/li><li>Dermatologic Effects:<\/li><li>-- monitor for growth or malignant changes in preexisting nevi<\/li><li>-- tissue atrophy may occur with long-term subQ administration; rotate injection site<\/li><li>Endocrine Metabolic Effects:<\/li><li>-- new or worsening hyperglycemia, glucose intolerance, or diabetes mellitus may occur; monitoring recommended, especially in patients with risk factors for diabetes<\/li><li>-- hypopituitarism; monitoring for other hormonal deficiencies recommended<\/li><li>-- undiagnosed or untreated hypothyroidism may prevent optimal response to somatropin and growth response in children; monitoring recommended<\/li><li>Gastrointestinal Effects:<\/li><li>-- rare cases of pancreatitis have been reported in both adult and pediatric patients, with greater risk in children<\/li><li>Immunologic Effects:<\/li><li>-- accelerated HIV replication may potentially occur; maintenance of antiretroviral therapy recommended during treatment<\/li><li>-- monitor for new or recurrent malignancy<\/li><li>-- local or systemic hypersensitivity may occur<\/li><li>Musculoskeletal Effects:<\/li><li>-- increased risk of slipped capital femoral epiphysis in pediatric patients<\/li><li>-- scoliosis may progress in with rapid growth in pediatric patients; monitoring recommended<\/li><li>-- carpal tunnel syndrome has been reported; discontinuation may be necessary<\/li><li>Neurologic:<\/li><li>-- intracranial hypertension with papilledema has been reported, increased risk in Prader-Willi syndrome, Turner syndrome, and chronic renal insufficiency patients; monitoring and possible discontinuation recommended<\/li><li>Ophthalmic Effects:<\/li><li>-- papilledema; initial screening and monitoring recommended; discontinue if condition occurs<\/li><li>Respiratory Effects:<\/li><li>-- acute respiratory failure in patients on replacement doses of somatropin may increase mortality risk<\/li><li>Other:<\/li><li>-- life-threatening and fatal gasping syndrome has occurred in neonatal and pediatric patients with benzyl alcohol exposure (a preservative in Bacteriostatic Water for Injection, USP diluent); monitor total daily metabolic load of benzyl alcohol from all sources<\/li><li>-- increased mortality risk in pediatric patients with Prader-Willi syndrome and severe obesity, history of upper airway obstruction or sleep apnea, or respiratory infection, especially males; baseline evaluation and ongoing monitoring recommended; treatment interruption may be required with signs of upper airway obstruction (eg, snoring) or new-onset sleep apnea<\/li><li>-- increased mortality has been reported in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma in patients on replacement doses of somatropin<\/li><\/ul>"},{"id":"925054-s-3-11","title":"Pregnancy Category","mono":"<ul><li>Somatropin: C (FDA)<\/li><li>Somatropin: B2 (AUS)<\/li><\/ul>"},{"id":"925054-s-3-12","title":"Breast Feeding","mono":"Somatropin: Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"925054-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Peripheral edema (growth hormone deficiency, 15%; HIV lipodystrophy, 18.8% to 45.4%; HIV wasting disease, 11.3% to 26.1%)<\/li><li><b>Dermatologic:<\/b>Injection site reaction (4.9%)<\/li><li><b>Endocrine metabolic:<\/b>Gynecomastia (up to 5.5%)<\/li><li><b>Musculoskeletal:<\/b>Arthralgia (up to 37.1%), Arthritis\/arthrosis (HIV wasting disease, 7.8% to 10.7%), Myalgia (Growth hormone deficiency, 8.3%; HIV lipodystrophy, 3.8% to 12.6%; HIV wasting disease, 17.9% to 30.4%)<\/li><li><b>Neurologic:<\/b>Headache (growth hormone deficiency, 18.3%), Hypesthesia (up to 6.7%), Paresthesia (growth hormone deficiency, 6.7%; HIV wasting disease, 7.4 to 7.9%)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Edema (up to 5.9%)<\/li><li><b>Endocrine metabolic:<\/b>Diabetes mellitus (0.1%), Hyperglycemia (7.1% to 8.8%), Hypothyroidism (5%), Impaired glucose tolerance (growth hormone deficiency, 10%)<\/li><li><b>Gastrointestinal:<\/b>Pancreatitis (rare)<\/li><li><b>Musculoskeletal:<\/b>Carpal tunnel syndrome (growth hormone deficiency, 5%), Scoliosis deformity of spine (0.2%)<\/li><li><b>Neurologic:<\/b>Intracranial hypertension, acute (less than 0.01%), Intracranial tumor<\/li><li><b>Other:<\/b>Neoplastic disease of uncertain behavior<\/li><\/ul>"},"6":{"id":"925054-s-6","title":"Drug Name Info","sub":{"0":{"id":"925054-s-6-17","title":"US Trade Names","mono":"<ul><li>Saizen<\/li><li>Serostim<\/li><li>Zorbtive<\/li><\/ul>"},"2":{"id":"925054-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Pituitary Hormone, Anterior<\/li><\/ul>"},"3":{"id":"925054-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"925054-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"925054-s-7","title":"Mechanism Of Action","mono":"Somatropin (rDNA origin), a recombinant polypeptide hormone, possesses primary structural identity to that of human growth hormone. In hormone-deficient pediatric patients, it induces skeletal growth at the epiphyseal plates of the long bones, as well as growth of skeletal muscles and body organs.<br\/>"},"8":{"id":"925054-s-8","title":"Pharmacokinetics","sub":[{"id":"925054-s-8-23","title":"Absorption","mono":"Bioavailability: 70% to 90% <br\/>"},{"id":"925054-s-8-24","title":"Distribution","mono":"Vd: 12 L +\/- 1.08 L <br\/>"},{"id":"925054-s-8-25","title":"Metabolism","mono":"Hepatic and Renal; protein catabolism <br\/>"},{"id":"925054-s-8-26","title":"Excretion","mono":"Renal <br\/>"},{"id":"925054-s-8-27","title":"Elimination Half Life","mono":"<ul><li>(Intramuscular), 3.4 h<\/li><li>(Intravenous), 0.6 h<\/li><li>(Subcutaneous), 1.75 h<\/li><\/ul>"}]},"9":{"id":"925054-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/><ul><li>Saizen(R): reconstitute with Bacteriostatic Water for Injection (use Sterile Water for Injection only if sensitivity occurs); do NOT shake, swirl gently, do NOT inject if solution is cloudy<\/li><li>Saizen(R): newborns, reconstitute using Sterile Water for Injection; do not use Bacteriostatic Water for Injection (toxicity with benzyl alcohol)<\/li><li>Saizen(R): solutions reconstituted with Bacteriostatic Water for Injection may store refrigerated for 14 days<\/li><\/ul><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>Serostim(R): reconstitute with appropriate diluent by aiming the liquid against the glass vial wall and swirl with a gentle rotary motion<\/li><li>Serostim(R): do not administer if the reconstituted product is cloudy immediately after reconstitution or after refrigeration (product reconstituted with Bacteriostatic Water for Injection only)<\/li><li>Serostim(R): product reconstituted with sterile water for injection should be used immediately; discard unused portion<\/li><li>Serostim(R): following refrigeration (product reconstituted with Bacteriostatic Water for Injection only), the presence of small colorless particles is not unusual<\/li><li>Serostim(R): rotate injection sites<\/li><li>Zorbtive(TM): reconstitute with appropriate diluent by aiming the liquid against the glass vial wall and swirl the vial with a gentle rotary motion<\/li><li>Zorbtive(TM): do not administer if the reconstituted product is cloudy immediately after reconstitution or after refrigeration<\/li><li>Zorbtive(TM): following refrigeration, the presence of small colorless particles is not unusual<\/li><li>Zorbtive(TM): allow refrigerated solution to come to room temperature prior to administration<\/li><li>Zorbtive(TM): a standard insulin-type subcutaneous syringe is recommended for administration<\/li><li>Zorbtive(TM): rotate the sites of administration<\/li><\/ul><\/li><\/ul>"},"10":{"id":"925054-s-10","title":"Monitoring","mono":"<ul><li>stimulation of linear growth is indicative of efficacy<\/li><li>improvements in signs and symptoms of HIV indicates efficacy<\/li><li>glucose levels; in all patients, particularly in those with risk factors for diabetes mellitus; closer monitoring is recommended for patients with preexisting type 1 or type 2 diabetes<\/li><li>fasting lipid panel; annually in adults with growth hormone deficiency, once maintenance dose has been achieved<\/li><li>HbA1c levels; at 6 to 12-month intervals in adults with growth hormone deficiency, after achieving maintenance dose<\/li><li>serum insulin-like growth factor (IGF-I) levels; in adults with growth hormone deficiency, adults, at 1- to 2-month intervals following initiation of therapy; once the maintenance dose has been achieved, and at 6- to 12-month intervals for dose-adjustment guidance<\/li><li>thyroid function tests; periodic<\/li><li>bone dual-energy X-ray absorptiometry (DEXA) scan, prior to initiation of therapy and if abnormal repeat evaluations at 2- to 3-year intervals during therapy<\/li><li>funduscopic examinations; before initiating treatment and periodically thereafter<\/li><li>progression or recurrence of neoplasm; routinely in patients with preexisting tumors and those with an increased risk of developing malignancy<\/li><li>respiratory infection; in patients with Prader-Willi syndrome<\/li><li>increased growth or potential malignant changes of preexisting nevi<\/li><li>progression of scoliosis<\/li><li>hormone replacement therapies; in patients with hypopituitarism during somatropin therapy<\/li><\/ul>"},"11":{"id":"925054-s-11","title":"How Supplied","mono":"<ul><li><b>Saizen Click Easy Cartridge<\/b><br\/>Injection Powder for Solution: 8.8 MG<br\/><\/li><li><b>Saizen<\/b><br\/><ul><li>Injection Powder for Solution: 8.8 MG<\/li><li>Subcutaneous Powder for Solution: 5 MG<\/li><\/ul><\/li><li><b>Serostim<\/b><br\/>Subcutaneous Powder for Solution: 4 MG, 5 MG, 6 MG<br\/><\/li><li><b>Zorbtive<\/b><br\/>Subcutaneous Powder for Solution: 8.8 MG<br\/><\/li><\/ul>"},"12":{"id":"925054-s-12","title":"Toxicology","sub":[{"id":"925054-s-12-31","title":"Clinical Effects","mono":"<b>SOMATROPIN<\/b><br\/>BACKGROUND: A biosynthetic polypeptide hormone with an amino acid sequence identical to human growth hormone. OVERDOSE: Data are limited. Hyperglycemia may occur with an acute exposure. Pituitary atrophy reported after long-term misuse.  Gigantism and\/or acromegaly may occur after long-term overdosage. ADVERSE EFFECTS: Peripheral edema, pancreatitis, hypo- and hyperglycemia, hypothyroidism, intracranial hypertension, tachycardia, hypertension, HA, agitation, fatigue, seizures, N\/V, hematuria, muscle and joint pain, and increased alkaline phosphatase have been reported.  OTHER: Somatropin products may contain benzyl alcohol (an antimicrobial preservative), which has been associated with toxicity in newborns. <br\/>"},{"id":"925054-s-12-32","title":"Treatment","mono":"<b>SOMATROPIN<\/b><br\/><ul><li>Decontamination: Not indicated. Subcutaneous administration.<\/li><li>Support: No antidote is available.  Overdose treatment is symptomatic and supportive<\/li><li>Monitoring of patient: Obtain baseline blood glucose level; repeat as indicated. Monitor thyroid function following an overdose.<\/li><\/ul>"},{"id":"925054-s-12-33","title":"Range of Toxicity","mono":"<b>SOMATROPIN<\/b><br\/>A minimum toxic dose has not been established. <br\/>"}]},"13":{"id":"925054-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause peripheral edema, increased tissue turgor, musculoskeletal pain, or influenza-like symptoms.<\/li><li>Drug may also cause progression of scoliosis, slipped capital femoral epiphysis in rapidly growing children, and carpal tunnel syndrome.<\/li><li>Instruct patient to report signs\/symptoms of hypo- or hyperglycemia, as antidiabetic treatment may need to be adjusted.<\/li><li>Patient should also monitor for and report increased growth or unusual changes to moles or other skin growths.<\/li><li>Teach patient proper technique and placement of injections.<\/li><li>Advise patient to rotate injection sites.<\/li><\/ul>"}}}